Bharat Book Bureau Provides the Trending Market Research Report on “US Cancer Antibodies Market, Drug Sales, Patent & Clinical Trials Outlook 2028”under Life Sciences Market Research Report Category. The report offers a collection of superior market research, market analysis, competitive intelligence and Market reports.

US Cancer Antibodies Market, Drug Sales, Patent & Clinical Trials Outlook 2028 Report Highlights:

• US Cancer Antibodies Market Opportunity: > US$ 85 Billion by 2028
• US Cancer Antibodies Market To Witness More Than 200% Absolute Growth
• Current & Future market Projections by Drugs & Therapeutic Class
• Clinical Trials Insight On by Company, Indication, Patient Segment and Phase
• Immune Checkpoint Inhibitors Dominating The Antibodies Sales: > 15 Billion In 2021
• Insight on FDA Approved 61 Cancer Antibodies Available in US Market
• Price, Dosage, Patent and Sales Insight on Cancer Antibodies Available In Market
• US Cancer Biosimilar Market Opportunity Insight



In last few years, therapeutic antibodies have gained maximum share in the US cancer therapeutics market. Their ability to specifically target the antigens on cancer has enabled the development of several targeted therapies. Further, advancement in the field of biotechnology has also led to development of new generation therapeutic agents. To date, several modalities of therapeutic antibodies including monoclonal antibodies, bispecific antibodies, antibody drug conjugates, and radiolabelled antibodies have been approved by US FDA which has shown robust response in the market. These are indicated for the management of several cancers including breast cancer, lung cancer, blood cancer, colorectal cancer, and other malignancies.

In 2021, immune checkpoint inhibitors segment hold the maximum share in the US cancer antibody market owing to their unique mechanism of action. The immune checkpoint inhibitors act by blocking the checkpoint protein, which are responsible for the prevention of cancer cells from the action of immune system. To date, 8 immune checkpoint inhibitors have entered the US market which is showing increasing sales every year. Apart from this, researchers are also evaluating other immune checkpoint including LAG-3, TIGIT, and others which are mainly present in clinical development. Relatlimab developed by Bristol Myers Squibb is a potential LAG-3 inhibitor which is expected to gain approval in market in March 2022, thus further boosting the growth of this segment during the forecast period.

The promising response of antibody therapeutics in the management of several cancers has gained a lot of attention from researchers. To date, more than 1000 clinical trials are ongoing in US, which are evaluating the role of therapeutic antibodies as monotherapy or combinational therapy in the management of cancer. For instance, researchers have developed next generation trispecific antibodies and bispecific antibody conjugate which are in initial stages of clinical development. The large number of clinical and preclinical studies suggests the promising future of antibody therapeutics in various cancers.

US is currently dominating the global cancer antibody market is mainly attributed to the surge in prevalence of cancer and rising awareness among population regarding the availability of targeted therapies. In addition, presence of major pharmaceutical companies in the region and rising investments by them also propels the growth of market during the forecast period. Apart from this, FDA also grants special designations to expedite the drug development process including orphan drug designation, fast track designation, breakthrough therapy designation, and others. Furthermore, development of favorable reimbursement policies also enhances their uptake of novel antibody therapeutics in the region.

The US cancer antibody therapeutic market is highly crowded and consists of several key players including Novartis, Amgen, Pfizer, Gilead Sciences, AstraZeneca, Bristol Myers Squibb, among others. For instance in 2021, Exelixis and Invenra have extended their discovery and licensing partnership to include 20 more oncology targets for multi-specific antibodies, antibody-drug conjugates, and the development of other biologic candidates. Further, AbbVie and I-Mab also announced collaboration for the development and commercialization of lemzoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. In addition, the two partners have the potential to expand the collaboration to additional transformative therapies.

As per our report findings, the US cancer antibody market is expected to surpass US$ 85 Billion by 2028. Rise in incidence of various cancer conditions, increase in popularity of advance therapies, and surge in geriatric population are the key factors driving the growth of the market. However, high cost involved in new drug development coupled with threat of failure and adverse effects associated with cancer antibody therapies is expected to restrain the growth of the market. Conversely, high potential of emerging economies and higher number of potential drugs in pipeline are expected to provide new opportunities for market players in future.

Browse our full report with Table of Content : https://www.bharatbook.com/report/1339164/us-cancer-antibodies-market-drug-sales-patent-clinical-trials-outlook

About Bharat Book Bureau:
Bharat Book is Your One-Stop-Shop with an exhaustive coverage of 4,80,000 reports and insights that includes latest Market Study, Market Trends & Analysis, Forecasts Customized Intelligence, Newsletters and Online Databases. Overall a comprehensive coverage of major industries with a further segmentation of 100+ subsectors.

Contact us at:
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Email: [email protected]
Website: www.bharatbook.com